Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alexion Optimistic Of Soliris' gMG Chances Despite Missing Ph III Target

Executive Summary

Alexion Pharmaceuticals Inc. is reassessing its regulatory strategy after Phase III data for its warhorse Soliris in myasthenia gravis, a rare neuromuscular disease, missed statistical significance on the primary endpoint but the company hopes regulators will give the therapy the benefit of the doubt after more data are generated.

Advertisement

Related Content

Stockwatch: ASCO Controversies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel